Cellectar Biosciences

CLRB

Market cap $19.5M

CLRB Hedge Fund Activity: Q1 2026 in Review

19 of the 8,129 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2026, worth a combined $813K — down 22% from $1.04M a quarter earlier.

Fund positioning in CLRB was balanced in Q1 2026: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $77.9K. The largest seller was DRW Securities, exiting entirely with an estimated $133K sold.

• 19 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2026, down from 20 in Q4 2025.
• Funds reported $813K of Cellectar Biosciences stock for Q1 2026, down 22% quarter-over-quarter.
• 4 funds opened new Cellectar Biosciences positions in Q1 2026 and 4 closed out, a net change of 0 holders.
• The largest Cellectar Biosciences buyer in Q1 2026 was Geode Capital Management, an estimated $77.9K added.
• The largest Cellectar Biosciences seller in Q1 2026 was DRW Securities, an estimated $133K sold.

Based on aggregated 13F filings for Q1 2026.